

8. Literaturverzeichnis

1. Rath W. Hypertensive Schwangerschaftserkrankungen. Gynäkologe. 1999; 32:432-442.
2. The World Health Report 2005-Make every mother and child count. Genf: World Health Organisation (WHO), 2006.
(Zugang 3.März 2006, auf http://www.who.int/whr2005_en.pdf)
3. Kashiwagi M, Zimmermann R, Beinder E. Pathophysiology of Pre-eclampsia: Update on the Role of Nitric Oxide. Curr Hypertens Rep 2003; 5:493-497.
4. Dekker GA, Sibai BM. Etiology and pathogenesis of preeclampsia: Current concepts. Am J Obstet Gynecol 1998; 1179:1359-1375.
5. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. Br Med J 2005; 330:1-7.
6. Axt-Fliedner R, Schröer A, Diedrich K. Molekulare Mechanismen der Präeklampsie. Gynäkologe 2004; 37:132-139.
7. Chesley LC, Annitto JE, Cosgrove RA. The familial factor in toxemia of pregnancy. Obstet Gynecol 1968; 32:301-311.
8. Arngrimsson R, Sigurdardottir S, Frigge ML, et al. A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. Hum Mol Genet 1999; 8:1799-1805.
9. Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. Br J Obstet Gynaecol 2004; 111:200-206.
10. Carr DB, Epplein M, Johnson CO, Easterling TR, Crichtlow CW. A sister's risk: family history as a predictor of preeclampsia. Am J Obstet Gynaecol 2005; 193:965-972.
11. Boyd PA, Lindenbaum RH, Redman C. Preeclampsia and trisomy 13: A possible association. Lancet 1987; 2:425-427.
12. Goldstein DP, Berkowitz RS. Current management of complete and partial molar pregnancy. J Reprod Med 1994; 39:139-146.
13. Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie-Nielsen E, Irgens LM. Fetal and maternal contributions to risk of pre-eclampsia: population based study. Br Med J 1998; 316:1343-1347.
14. Arngrimsson R, Bjornsson S, Geirsson RT, Bjornsson H, Walker JJ, Snaedal G. Genetic and familial predisposition to eclampsia and pre-eclampsia in a defined population. Br J Obstet Gynaecol 1990; 97:762-769.

15. Esplin MS, Fausett MB, Fraser A, et al. Paternal and maternal components of the predisposition to preeclampsia. *N Engl J Med* 2001; 344:867-872.
16. Ward K, Hata A, Jeunemaitre X, et al. A molecular variant of angiotensinogen associated with preeclampsia. *Nat Genet.* 1993; 4:59-61.
17. Kupferminc MJ, Eldor A, Steinman N, et al. Increased frequency of genetic thrombophilia in women with complications of pregnancy. *N Engl J Med.* 1999; 340:9-13
18. Dizon-Townson D, Hutchison C, Silver R, Branch DW, Ward K. The factor V Leiden Mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. *Thromb Haemost.* 1995; 74: 1029-1031.
19. Banyasz I, Szabo S, Bokodi G, et al. Genetic polymorphisms of vascular endothelial growth factor in severe pre-eclampsia. *Mol Hum Reprod.* 2006; 12: 233-236.
20. Kim YJ, Roger AW, Chen K, Smith JL, Murray JC, Merrill DC. Lipoprotein Lipase Gene Mutations and the Genetic Susceptibility of Preeclampsia. *Hypertension.* 2001; 38:992-996.
21. Marsden PA, Heng HHQ, Scherer SW, et al. Structure and Chromosomal Localization of the Human Constitutive Endothelial Nitric Oxide Synthase Gene. *J Biol Chem* 1993; 268:17478-17488.
22. Schmidt HHW, Walter U. NO at work. Review. *Cell* 1994; 78:919-925.
23. Seligman SP, Buyon JP, Clancy RM, Young BK, Abramson SB. The role of nitric oxide in the pathogenesis of preeclampsia. *Am J Obstet Gynaecol* 1994; 171:944-948.
24. Rao S, Austin H, Davidoff MN, Zafari AM. Endothelial nitric oxide synthase intron 4 is a marker for coronary artery disease in African-American and Caucasian men. *Ethn Dis* 2005; 15:191-197.
25. Gardemann A, Lohre J, Cayci S, Katz N, Tillmanns H, Haberbosch W. The T allele of the missense Glu 298 Asp endothelial nitric oxide synthase gene polymorphism is associated with coronary heart disease in younger individuals with high atherosclerotic risk profile. *Atherosclerosis* 2002; 160:167-175.
26. Granath B, Taylor RR, van Bockxmeer FM, Mamotte CD. Lack of evidence for association between endothelial nitric oxide synthase gene polymorphisms and coronary artery disease in the Australian Caucasian population. *J Cardiovasc Risk.* 2001; 8:235-241.
27. Sigusch HH, Surber R, Lehmann MH, et al. Lack of association between 27-bp repeat polymorphism in intron 4 of the endothelial nitric oxide synthase gene and the risk of coronary artery disease. *Scand J Clin Lab Invest* 2000; 60:229-236.

28. Poirier O, Mao C, Mallet C, et al. Polymorphisms of the endothelial nitric oxide synthase gene-no consistent association with myocardial infarction in the ECTIM study. *Eur J Clin Invest* 1999; 29:284-290.
29. Jeerooburkhan N, Jones LC, Bujac S, et al. Genetic and Environmental Determinants of Plasma Nitrogen Oxides and Risk of Ischemic Heart Diseases. *Hypertension* 2001; 38:1054-1061.
30. Miyamoto Y, Saito Y, Kajiyama N, et al. Endothelial Nitric Oxide Synthase Gene Is Positively Associated With Essential Hypertension. *Hypertension* 1998; 32:3-8.
31. Uwabo J, Soma M, Nakayama T, Kanmatsuse K. Association of a Variable Number of tandem Repeats in the Endothelial Constitutive Nitric Oxide Synthase Gene With Essential Hypertension in Japanese. *Am J Hypertens* 1998; 11:125-128.
32. Benjafeld A, Morris B. Association Analyses of Endothelial Nitric Oxide Synthase Gene Polymorphisms in Essential Hypertension. *Am J Hypertens* 2000; 13:994-998.
33. Hoffmann MM, Winkelmann BR, Schneider S, et al. Endothelial nitric oxide synthase gene Glu298->Asp variant-Association with arterial hypertension, but not with coronary artery disease. *Atherosclerosis* 2000; 151:254.
34. Akar N, Akar E, Cin S, Deda G, Avcu F, Yalcin A. Endothelial nitric oxide synthase intron 4, 27 bp repeat polymorphism in Turkish patients with deep vein thrombosis and cerebrovascular accidents. *Thromb Res* 1999; 94:63-64.
35. Freedman BI, Yu H, Anderson P, Roh BH, Rich SS, Bowden DW. Genetic analysis of nitric oxide and endothelin in end-stage renal disease. *Nephrol Dial Transplant* 2000; 15:1794-1800.
36. Krex D, Fortun S, Kuhlisch E, Schackert HK, Schackert G. The role of endothelial nitric oxide synthase genetic variants in European patients with intracranial aneurysms. *J Cereb Blood Flow Metab* 2006:1-6.
37. Panza JA, Quyyumi AA, Brush JEJ, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. *N Engl J Med* 1990; 323:22-27.
38. Huang PL, Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. *Nature* 1995; 377:239-242.
39. Shesely EG, Maeda N, Kim HS, et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. *Proc Natl Acad Sci USA* 1996; 93:13176-13181.
40. Baylis C, Mitruka B, Deng A. Chronic blockade of nitric oxide synthesis in the rat produces systemic hypertension and glomerular damage. *J Clin Invest* 1992; 90:278-281.

41. Manning RDJ, Hu L, Mizelle HL, Montani JP, Norton MW. Cardiovascular responses to long-term blockade of nitric oxide synthesis. *Hypertension* 1993; 22:40-48.
42. Haynes WG, Noon JP, Walker BR, Webb DJ. Inhibition of nitric oxide synthesis increases blood pressure in healthy humans. *J Hypertens* 1993; 11:1375-1380.
43. Conrad KP, Vernier KA. Plasma level, urinary excretion, and metabolic production of cGMP during gestation in rats. *Am J Physiol* 1989; 257:847-853.
44. Conrad KP, Joffe GM, Kruszyna H, et al. Identification of increased nitric oxide biosynthesis during pregnancy in rats. *FASEB J.* 1993; 7:566-571.
45. Nelson SH, Steinsland OS, Wang Y, Yallampalli C, Dong YL, Sanchez JM. Increased Nitric Oxide Synthase Activity and Expression in the Human Uterine Artery during Pregnancy. *Circ Res* 2000; 87:406-411.
46. Yallampalli C, Garfield RE. Inhibition of nitric oxide synthesis in rats during pregnancy produces signs similar to those of preeclampsia. *Am J Obstet Gynaecol* 1993; 169:1316-1320.
47. Talosi G, Endreffy E, Turi S, Nemeth I. Molecular and Genetic Aspects of Preeclampsia: State of the Art. *Mol Genet Metab* 2000; 71:565-572.
48. Brennecke SP, Gude NM, Di Iulio JL, King RG. Reduction of placental nitric oxide synthase activity in pre-eclampsia. *Clin Sci* 1997; 93:51-55.
49. Kublickiene KR, Lindblom B, Krüger K, Nisell H. Preeclampsia: Evidence for impaired shear stress-mediated nitric oxide release in uterine circulation. *Am J Obstet Gynaecol* 2000; 183:160-166.
50. Maxwell JA. Mechanisms of Dysfunction of the Nitric Oxide Pathway in Vascular Diseases. *Nitric Oxide* 2001; 6:101-124.
51. Nakayama M, Yasue H, Yoshimura M, et al. T-786>C mutation in the flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. *Circulation* 1999; 99:2855-2857.
52. Suryanarayana V, Rao L, Kanakavalli M, Padmalatha V, Deenadayal M, Singh L. Recurrent early pregnancy loss and endothelial nitric oxide synthase gene polymorphisms. *Arch Gynecol Obstet* 2006; 274:119-124
53. Bonnardeaux A, Nandaud S, Charru A, Jeunemaitre X, Corvol P, Soubrier F. Lack of evidence for linkage of the endothelial cell nitric oxide synthase gene to essential hypertension. *Circulation* 1995; 91:96-102.
54. Miyahara K, Kawamoto T, Sase K, et al. Cloning and structural characterization of the human endothelial nitric-oxide-synthase gene. *Eur J Biochem* 1994; 223:719-726.

55. Nadaud S, Bonnardeaux A, Lathrop M, Soubrier F. Gene structure, polymorphism and mapping of the human endothelial nitric oxide synthase gene. *Biochem Biophys Res Commun* 1994; 198:1027-1033.
56. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. *Nat Med* 1996; 2:41-45.
57. Hooper WC, Lally C, Austin H, et al. The Relationship Between Polymorphisms in the Endothelial Cell Nitric Oxide Synthase Gene and the Platelet GPIIIa Gene with Myocardial Infarction and Venous Thromboembolism in African Americans. *Chest* 1999; 116:880-886.
58. Tempfer CB, Dorman K, Deter RL, O'Brien WE, Gregg AR. An endothelial Nitric Oxide Synthase Gene Polymorphism is associated with Preeclampsia. *Hypertens Pregnancy* 2001; 20:107-118.
59. Serrano NC, Casas JP, Diaz AL, Paez C. Endothelial NO Synthase Genotype and Risk of Preeclampsia. *Hypertension* 2004; 44:702-707.
60. Tsukada T, Yokoyama K, Arai T, et al. Evidence of Association of the eNOS Gene Polymorphism with Plasma NO Metabolite Levels in Humans. *Biochem Biophys Res Commun* 1998; 245:190-193.
61. Wang XL, Mahaney MC, Sim AS, et al. Genetic Contribution of the Endothelial Constitutive Nitric Oxide Synthase Gene to Plasma Nitric Oxide Levels. *Arterioscler Thromb Vasc Biol* 1997; 17:3147-3153.
62. Wang XL, Sim AS, Wang MX, Murell GAC, Trudinger B, Wang J. Genotype dependent and cigarette specific effects on endothelial nitric oxide synthase gene expression and enzyme activity. *FEBS Letters* 2000; 471:45-50.
63. Metzger IF, Souza-Costa DC, Marroni AS, et al. Endothelial nitric oxide synthase gene haplotypes associated with circulating concentrations of nitric oxide products in healthy men. *Pharmacogenet Genomics* 2005; 15:565-570.
64. Wang XL, Wang J. Endothelial Nitric Oxide Synthase Gene Sequence Variations and Vascular Disease. *Mol Genet Metab* 2000; 70:241-251.
65. Tempfer CB, Unfried G, Zeillinger R, Hefler LA, Nagele F, Huber JC. Endothelial nitric oxide synthase gene polymorphism in women with idiopathic recurrent miscarriage. *Hum Reprod* 2001; 16:1644-1647.

66. Song J, Yoon Y, Park KU, et al. Genotype-specific Influence on Nitric Oxide Synthase Gene Expression, Protein Concentrations, and Enzyme Activity in Cultured Human Endothelial Cells. *Clin Chem* 2003; 49:847-852.
67. Wang J, Dudley D, Wang XL. Haplotype-Specific Effects on Endothelial NO Synthase Promoter Efficiency: Modifiable by Cigarette Smoking. *Arterioscler Thromb Vasc Biol* 2002; 22:1-4.
68. Ou H, Shen YH, Utama B, et al. Effect of Nuclear Actin on Endothelial Nitric Oxide Synthase Expression. *Arterioscler Thromb Vasc Biol* 2005; 25:2509-2514.
69. Hakli T, Romppanen EL, Hiltunen M, Helisalmi S, Punnonen K, Heinonen S. Endothelial nitric oxide synthase polymorphism in preeclampsia. *J Soc Gynecol Investig.* 2003; 10:154-157.
70. Bashford MT, Hefler LA, Vertrees TW, Roa BB, Gregg AR. Angiotensinogen and endothelial nitric oxide synthase gene polymorphisms among Hispanic patients with preeclampsia. *Am J Obstet Gynaecol* 2001; 184:1345-1351.
71. Grandone E, Colaizzo D, Martinelli P, et al. Does Endothelial Nitric Oxide Gene Variation Play a Role in the Occurrence of Hypertension in Pregnancy? *Hypertens Pregnancy* 2003; 22:149-155.
72. Mullis KB, Faloona FA. Specific Synthesis of DNA in vitro via a Polymerase-Catalyzed Chain Reaction. *Methods in Enzymology* 1987;155: 335-350.
73. Sanger F, Nicklens S, Coulson AR. DNA Sequencing with chain-terminating inhibitors. *Proc.Natl.Acad.Sci.USA* 1977; 74: 5463-5467
74. Brown MA, Buddle,ML. What's in a name? Problems with the classification of Hypertension in Pregnancy. *J Hypertens* 1997; 15:1094-1054.
75. Wilson ML, Goodwin TM, Pan VL, Ingles SA. Molecular Epidemiology of Preeclampsia. *Obstet Gynecol Surv* 2003; 58:39-66.
76. Knowler WC, Williams RC, Pettitt DJ, Steinberg AG. Gm3,5,13,14 and Type 2 Diabetes Mellitus: An Association in American Indians with Genetic Admixture. *Am J Hum Genet* 1988; 43:520-526.
77. Tanus-Santos JE, Desai M, Flockhart DA. Effects of ethnicity on the ditribution of clinically relevant endothelial nitric oxide variants. *Pharmacogenetics* 2001; 11:719-725.
78. Marroni AS, Metzger IF, Souza-Costa DC, et al. Consistent interethnic differences in the ditribution of clinically relevant endothelial nitric oxide synthase genetic polymorphisms. *Nitric Oxide* 2005; 12:177-182.

79. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. *Lancet* 2003; 361:865-872.
80. Cnattingius S, Reilly M, Pawitan Y, Lichtenstein P. Maternal and Fetal Genetic Factors Account for Most of Familial Aggregation of Preeclampsia. *Am J Med Genet* 2004; 130A:365-371.
81. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. *Lancet* 2001; 357:53-56.
82. Arngrimmson R, Hayward C, Nadaud S. Evidence for a familial pregnancy-induced hypertension locus in the eNOS-c region. *Am J Hum Genet* 1997; 61:354-362.
83. Guo G, Lade JA, Wilton AN, et al. Genetic susceptibility to preeclampsia and chromosome 7q36. *Hum Genet* 1999; 105:641-647.
84. Lewis I, Lachmeijer G, Downing S, et al. Failure to Detect Linkage of Preeclampsia to the Region of the NOS3 Locus on Chromosome 7q. *Am J Hum Genet* 1999; 64:310-313.
85. Lade JA, Moses EK, Guo G, et al. The eNOS Gene: A Candidate for the Preeclampsia susceptibility Locus. *Hypertens Pregnancy* 1999; 18:81-93.
86. Moses EK, Lade JA, Guo G, et al. A Genome Scan in Families from Australia and New Zealand Confirms the Presence of a Maternal Susceptibility Locus for Pre-eclampsia, on Chromosome 2. *Am J Hum Genet* 2000; 67:1581-1585.
87. Lachmeijer AMA, Arngrimmson R, Bastiaans EJ, Frigge ML, Pals G, Sigurdardottir S. A genome-wide scan for preeclampsia in The Netherlands. *Eur J Hum Genet* 2001; 9:758-764.
88. Harrison GA, Humphrey KE, Jones N, Badenhop RB, Guo G, Elakis G. A genomewide linkage study of preeclampsia/ eclampsia reveals evidence for a candidate region on 4q. *Am J Hum Genet* 1997; 60:1158-1167.
89. Sandrim VC, Coelho EB, Nobre F, Arado GM, Lanchote VL, Tanus-Santos JE. Susceptible and protective eNOS haplotypes in hypertensive black and white subjects. *Atherosclerosis* 2006; 186:428-432
90. GOPEC-Consortium. Disentangling Fetal and Maternal Susceptibility for Pre-eclampsia: A British Multicenter Candidate-Gene Study. *Am J Hum Genet* 2005; 77:127-131.
91. Terwilliger JD, Weiss KM. Linkage disequilibrium mapping of complexe disease: fantasy or reality ? *Curr Opin Biotechnol* 1998; 9:578-594.
92. Wattanapitayakul SK, Mihm MJ, Young AP, Bauer JA. Therapeutic implications of human endothelial nitric oxide synthase gene polymorphism. *Trends Pharmacol Sci* 2001; 22:361-368.

93. Chien PFW, Arnott N, Owen P, Khan KS. How useful is uterine artery Doppler flow velocimetry in the prediction of pre-eclampsia, intrauterine growth retardation and perinatal death? An overview. *Br J Obstet Gynaecol* 2000; 107:196-208.
94. Conde-Agudelo A, Villar J, Lindheimer M. World Health Organization Systematic Review of Screening Tests for Preeclampsia. *Obstet Gynecol* 2004; 104:1367-1391.
95. Dekker GA, Sibai B. Primary, secondary, and tertiary prevention of pre-eclampsia *Lancet* 2001; 357:209-215.
96. Duley L, Henderson-Smart DJ, Knight M, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications (Review). *The Cochrane Database of Systematic Reviews* 2003:1-19.
97. Chapell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock-Jones DS. A longitudinal study of biochemical variables in women at risk of preeclampsia. *Am J Obstet Gynaecol* 2002; 187:127-136.
98. Walther T, Wessel N, Malberg H, Voss A, Stepan H, Faber R. a combined technique for predicting pre-eclampsia: concurrent measurement of uterine perfusion and analysis of heart rate and blood pressure variability. *J Hypertens* 2006; 24:747-750.
99. Krause MM, Homuth V, Schmider A, Luft, FC. Genetische Grundlagen der schwangerschaftsinduzierten Hypertonie. *Gynäkologe* 2001; 34:503-509
100. Ruano R, Fontes RS, Zugaib M. Prevention of Preeclampsia with low-dose Aspirin-a systemativ review and meta-analysis of the main randomized controlled trials. *Clinics* 2005; 60:407-414.
101. Caritis S, Sibai B, Hauth J, et al. Low-Dose Aspirin to Prevent Preeclampsia in Women at High Risk. *N Engl J Med* 1998; 388:701-705.
102. Levine RJ, Hauth J, Curet LB, et al. Trial of calcium to Prevent Preeclampsia. *N Engl J Med* 1997; 337:69-76.
103. Beazley D, Ahokas R, Livingston J, Griggs M, Sibai BM. Vitamin C and E supplementation in women at high risk for preeclampsia: A double-blind, placebo-controlled trial. *Am J Obstet Gynaecol* 2005; 192:520-521.
104. Rumbold A, Duley L, Crowther C, Haslam R. Antioxidants for preventing pre-eclampsia (Review). *The Cochrane Database of Systematic Reviews* 2005:1-62.
105. Poston L, Briley A, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. *Lancet* 2006; 367:1145-1154.

106. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a meta-analysis. *Lancet* 2000; 355:87-92.
107. Altman D, Carroli G, Duley L, et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. *Lancet* 2002; 359:1877-1890.
108. Ganzevoort W, Rep A, Bonsel GJ, et al. A randomised controlled trial comparing two temporising management strategies, one with and one without plasma volume expansion, for severe and early onset pre-eclampsia. *Br J Obstet Gynaecol* 2005; 112:1358-1368.
109. Marin R, Gorostidi M, Portal CG, Sanchez M, Sanchez E, Alvarez J. Long-Term Prognosis of Hypertension in Pregnancy. *Hypertens Pregnancy* 2000; 19:199-209.
110. Smith GCS, Pell JP, Walsh D. Pregnancy complications and maternal risk of ischemic heart disease: a retrospective cohort study of 129 290 births. *Lancet* 2001; 357:2002-2006.
111. Ness RB, Hubel CA. Risk for Coronary Artery Disease and Morbid Preeclampsia: A Commentary. *Ann Epidemiol* 2005; 15:726-733.
112. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study. *Br Med J* 2001; 323:1213-1217.
113. Funai EF, Friedlander Y, Paltiel O, et al. Long-Term Mortality After Preeclampsia. *Epidemiology* 2005; 16:206-215.
114. Brown DW, Dueker N, Jamieson DJ, et al. Preeclampsia and the Risk of Ischemic Stroke Among Young Women. *Stroke* 2006; 37:1055-1059.
115. Barker DJ, Gluckman PD, Godfrey KM, Harding JE, Owens JA, Robinson JS. Fetal nutrition and cardiovascular disease in later life. *Lancet* 1993; 341:938-941.
116. Godfrey KM, Barker DJ. Fetal nutrition and adult disease. *Am J Clin Nutr* 2000; 71:1344-1352.
117. van Wassenaer A. Neurodevelopmental Consequences of being born SGA. *Pediatr Endocrinol Rev* 2005; 2:372-377.
118. Johansson S, Iliadou A, Bergvall N, Tuvemo T, Norman M, Cnattingius S. Risk of high blood pressure among young men increases with the degree of immaturity at birth. *Circulation* 2005; 112:3430-3436.
119. *Wie Frauen leben. Frauen in Deutschland 2006*. Wiesbaden: Statistisches Bundesamt, 2006.
(Zugang am 3.03.2006 auf http://www.destatis.de/allg/d/veroe/d_blickpktfrauen.htm)

120. DIR-Jahrbuch 2004. Bad Segeberg: DIR-Bundesgeschäftsstelle bei der Ärztekammer Schleswig-Holstein, 2005. (Zugang am 8.04.2006 auf http://www.meb.uni-bonn.de/frauen/DIR_downloads/dirjahrbuch2004.pdf)
121. Nakatsuka M, Takata M, Tada K, et al. A Long-term Transdermal Nitric Oxide Donor Improves Uteroplacental Circulation in Women With Preeclampsia. *J Ultrasound Med* 2002; 21:831-836.
122. Cetin A, Yurtcu N, Guvenal T, Imir AG, Duran B, Cetin M. The Effect of Glyceryl Trinitrate on Hypertension in Women with Severe Preeclampsia, HELLP-Syndrome and Eclampsia. *Hypertens Pregnancy* 2004; 23:37-46.
123. Staff AC, Berge L, Haugen G, Lorentzen B, Mikkelsen B, Henriksen T. Dietary supplementation with L-arginine or placebo in women with pre-eclampsia. *Acta Obstet Gynecol Scand* 2004; 83:103-107.
124. Rytlewski K, Olszanecki R, Korbut R, Zdebski Z. Effects of prolonged oral supplementation with L-arginine on blood pressure and nitric oxide synthesis in preeclampsia. *Eur J Clin Invest* 2005; 35:32-37.
125. Beinder E, Mohaupt M. NO-Donatoren zur Verhütung und Behandlung präeklampsischer Erkrankungen. *Gynäkologe* 1999; 32:768-775.
126. Förstermann U, Münzel T. Endothelial Nitric Oxide Synthase in Vascular Disease -From Marvel to Menace. *Circulation* 2006; 113:1708-1714.